TARDBP and amyotrophic lateral sclerosis: Given that mutations in TDP-43 account for only 5% of fALS cases, it will be important to assess whether antibody-based therapy is able to reduce aggregation of the wild-type protein, as this is the more common TDP-43 protein species found in ALS patients with TDP-43 proteinopathy.